Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Neurology, Psychology, Mental Health, CNS, Pain & TBI Companies (Pharmaceuticals, Drugs, Biotechnology, Biosimilars) _ Neurodegenerative; Neuromuscular, Neuropsychiatric
Trace Neuroscience

Organization & Developments: Trace Neuroscience

Parents

*Developing novel genomic therapies that restore UNC13A protein to re-establish healthy communication between nerves and muscle cells impacted by neurodegenerative disease
*Trace Neuroscience’s lead program is an antisense oligonucleotide (ASO) designed to preserve and potentially improve muscle function in people living with amyotrophic lateral sclerosis (ALS)
2024: Trace Neuroscience Launches With $101 Million Series A Financing to Expand Genomic Medicine for Neurodegenerative Diseases